Vaxcyte And Lonza Expand Collaboration For Global Commercial Manufacturing Of Broad-Spectrum Pneumococcal Conjugate Vaccines
Portfolio Pulse from Benzinga Newsdesk
Vaxcyte, Inc. (NASDAQ:PCVX) and Lonza have expanded their collaboration with a new commercial manufacturing agreement. This agreement supports the potential global commercialization of Vaxcyte's pneumococcal conjugate vaccine (PCV) candidates, VAX-24 and VAX-31. Lonza will provide a custom-built manufacturing suite at its Visp site to manufacture key components for Vaxcyte's PCV franchise. The suite is expected to meet the potential long-term market demand for both adult and pediatric populations globally. Equipment installation is expected to begin in 2024, creating up to 300 new jobs.
October 16, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaxcyte's expanded collaboration with Lonza for the commercial manufacturing of its PCV candidates, VAX-24 and VAX-31, could potentially boost its stock. The agreement could help meet long-term market demand and create up to 300 new jobs.
The expanded collaboration with Lonza could potentially increase Vaxcyte's production capacity for its PCV candidates, VAX-24 and VAX-31. This could help meet the potential long-term market demand and create up to 300 new jobs, which could positively impact Vaxcyte's stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100